Who has been buying remed stock?

4 distinct insiders have filed 10 disclosed insider purchases in remed (302550), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does remed have?

remed has 10 buy-side and 0 sell-side disclosures on record, covering ₩27M ($19K) in total reported value, spanning 2026-01-27 to 2026-04-09.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

remed 302550

Company

리메드remed

Insiders

Buys

Total Value

₩27M ($19K)

Avg Return

+10.21%

Last Filing

2026-04-09

remed (302550) has 10 disclosed insider purchases and 0 disclosed disposals on record, filed by 4 distinct insiders. Together those filings cover ₩27M ($19K) in reported transaction value. The earliest filing StockDrifts holds for remed is dated 2026-01-27; the most recent is 2026-04-09. Across these filings the average return since disclosure is +10.21%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-04-09	BUY	Market Buy	김태군 Taegun Kim	Executive Officer (CTO)	3.3K	₩2,910	+9.3%	₩10M ($7K)
2026-02-25	BUY	Market Buy	신대현 Daehyun Shin	Executive Officer (CPO)	2.5K	-	-	-
2026-02-05	BUY	Market Buy	송종은 Song Jong-eun	Executive Officer (CSO)	300	₩2,800	+12.5%	₩840K ($583)
2026-02-05	BUY	Market Buy	송종은 Song Jong-eun	Executive Officer (CSO)	1.0K	₩2,800	+12.5%	₩3M ($2K)
2026-02-03	BUY	Market Buy	송종은 Song Jong-eun	Executive Officer (CSO)	600	₩2,810	+12.1%	₩2M ($1K)
2026-02-02	BUY	Market Buy	송종은 Song Jong-eun	Executive Officer (CSO)	600	₩2,760	+14.1%	₩2M ($1K)
2026-01-30	BUY	Market Buy	송종은 Song Jong-eun	Executive Officer (CSO)	600	₩2,860	+10.1%	₩2M ($1K)
2026-01-28	BUY	Market Buy	신대현 Daehyun Shin	Executive Officer (CPO)	100	₩2,955	+6.6%	₩296K ($205)
2026-01-27	BUY	Market Buy	이정수 Jeongsoo Lee	Executive Officer (CFO)	3.0K	₩2,935	+7.3%	₩9M ($6K)
2026-01-27	BUY	Market Buy	이정수 Jeongsoo Lee	Executive Officer (CFO)	45	₩2,935	+7.3%	₩132K ($92)

Frequently asked questions

Who has been buying remed stock?: 4 distinct insiders have filed 10 disclosed insider purchases in remed (302550), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does remed have?: remed has 10 buy-side and 0 sell-side disclosures on record, covering ₩27M ($19K) in total reported value, spanning 2026-01-27 to 2026-04-09.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.